Ivonescimab

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) [1][2][3][4][5].

Product Specifications

CAS Number

[2428381-53-5]

Product Name Alternative

AK112

UNSPSC

12352203

Target

PD-1/PD-L1; VEGFR

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ivonescimab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Ivonescimab]

Molecular Weight

(201.1 kDa)

References & Citations

[1]Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9: |[2]Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10: |[3]Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517. |[4]Dhillon S. Ivonescimab: First Approval. Drugs. 2024 Sep;84 (9) :1135-1142. |[5]Fang W, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024 Aug 20;332 (7) :561-570.